Device Trial Radar · NCT04877899
Mazankowski Alberta Heart Institute (MAHI) EchoGo Discovery 1 Protocol
Last checked: Nov 19, 2026Latest source record: Sep 5, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
250
Planned (sponsor's estimate)
Start
Oct 8, 2020
Primary completion
Mar 31, 2021
Study completion Nov 30, 2021
Sponsor
- Lead sponsor
- Ultromics LtdNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- Mazankowski Alberta Heart Institute
- First posted
- May 7, 2021
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to compare conventionally acquired Left Ventricle Ejection Fraction (LVEF) and Global Longitudinal Strain (GLS) data to Artificial Intelligence (AI) driven automated processing of 2 dimensional contrast and 2 dimensional non-contrast resting transthoracic echocardiograms for application in the assessment of patients undergoing chemotherapy with cardiotoxic drugs. This is a single-centre retrospective study which utilizes echocardiographic DICOM image and meta-data datasets received from a Canadian site. Data processed using the AI driven automated processing will be compared to conventionally acquired LVEF and GLS measurements and results will be analysed to determine accuracy and precision.
Conditions
- Cardiotoxicity
- Cancer
Interventions
EchoGoDevice
EchoGo Core is a stand-alone software application. Echocardiograms should be acquired under the supervision of a physician and standard clinical protocols which includes focused apical 2, 3 and 4 chamber views. The results contain calculated measurements that will be returned to the interpreting physician. These results are intended as an additional input to standard diagnostic pathways and should only be used by a board-certified cardiologist/physician. EchoGo Core is intended to be used for the quantification and reporting of results of cardiovascular function to support physician diagnosis. EchoGo Core is indicated for use in adult populations.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Compare the performance of automated EF and GLS measurements in resting transthoracic echocardiograms against conventional measurement acquisition.Time frame: Baseline
- Compare the performance of automated EF and GLS measurements in resting transthoracic echocardiograms against conventional measurement acquisition.Time frame: Follow up (up to 1 year)
- Compare the performance of automated EF and GLS measurements in resting transthoracic echocardiograms with and without the application of contrast agents.Time frame: Baseline
1 more outcomes with a free account
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mazankowski Alberta Heart Institute
Edmonton, Alberta, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.